Figure 2.
Comparison of median progression‐free survival to first‐line platinum‐based combination chemotherapy in patients with BRAF mutations versus EGFR (A) or KRAS mutations (B).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.